To date, we have funded our operations through public and private placements of equity securities, upfront, milestone, option exercise, reservation fee, expense reimbursement, sponsored research payments received from our collaborators, recharging of third party costs and interest income from the investment of our cash, cash equivalents and financial assets.

filing / Mar 12, 2026 / receipt

are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the emergence of variants, the transition to endemic status, travel restrictions and social distancing in Switzerland, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in countries around the world to c

filing / Mar 12, 2026 / receipt

In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs.

filing / Mar 12, 2026 / receipt

Dr. Patrick Amstutz | 50 | Chief Executive Officer and Director

filing / Mar 12, 2026 / receipt

Renate Gloggner | 55 | EVP People and Community

filing / Mar 12, 2026 / receipt

Dr. Philippe Legenne | 60 | Chief Medical Officer

filing / Mar 12, 2026 / receipt

Dr. Martin Steegmaier | 60 | Chief Scientific Officer

filing / Mar 12, 2026 / receipt

Dr. Michael Tobias Stumpp | 53 | EVP Projects

filing / Mar 12, 2026 / receipt

Alexander Zürcher | 50 | Chief Operating Officer

filing / Mar 12, 2026 / receipt

William M. Burns | 78 | Chairman of the Board

filing / Mar 12, 2026 / receipt

Dr. Agnete Fredriksen | 48 | Director

filing / Mar 12, 2026 / receipt

Dr. Dominik Höchli | 58 | Director

filing / Mar 12, 2026 / receipt